Bicara Therapeutics (NASDAQ:BCAX) Price Target Lowered to $41.00 at HC Wainwright

Bicara Therapeutics (NASDAQ:BCAX) had its price target dropped by HC Wainwright from $44.00 to $41.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 183.34% from the stock’s previous close.

Several other research analysts have also recently commented on BCAX. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.01 target price on shares of Bicara Therapeutics in a report on Thursday, March 13th. Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a report on Thursday, March 27th. Wells Fargo & Company assumed coverage on Bicara Therapeutics in a report on Thursday, April 17th. They set an “underweight” rating and a $8.00 target price on the stock. Finally, Wedbush restated an “outperform” rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research report on Thursday, March 27th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Bicara Therapeutics Stock Up 5.6%

Shares of Bicara Therapeutics stock opened at $14.47 on Friday. Bicara Therapeutics has a 1 year low of $8.91 and a 1 year high of $28.09. The business has a fifty day simple moving average of $12.81 and a two-hundred day simple moving average of $15.38.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.28). Sell-side analysts predict that Bicara Therapeutics will post -2.59 EPS for the current year.

Institutional Trading of Bicara Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System bought a new position in shares of Bicara Therapeutics in the 4th quarter valued at $25,000. CWM LLC bought a new position in Bicara Therapeutics in the first quarter valued at about $29,000. Spire Wealth Management acquired a new stake in shares of Bicara Therapeutics during the fourth quarter valued at about $31,000. BNP Paribas Financial Markets acquired a new stake in shares of Bicara Therapeutics during the fourth quarter valued at about $32,000. Finally, Legal & General Group Plc bought a new stake in shares of Bicara Therapeutics during the fourth quarter worth about $33,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.